Shares of Altimmune Inc. ALT, -37.39% tumbled 44.4% in premarket trading on Wednesday after the company shared new data from an early-stage clinical trial for its experimental treatment for non-alcoholic fatty liver disease that failed to impress investors. The Phase 1b study met both the primary and secondary endpoints of reduction in liver fat content and weight loss, respectively. Two of the 94 patients left the study due to gastrointestinal side effects; both were taking pemvidutide and not placebo. Altimmune’s stock has gained 122.5% so far this year, while the broader S&P 500 SPX, +0.09% has declined 13.7%.
